LA JOLLA, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc., formerly known as Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA) announced today that it will host a scientific briefing on Thursday, January 29, 2009, at 12:00 p.m. EST in New York City.
The keynote speaker will be Jonathan S. Stamler, MD, the George Barth Geller Professor for Research in Cardiovascular Diseases and a Professor of Medicine and of Biochemistry at Duke University Medical Center in Durham, North Carolina. Dr. Stamler will review his research work at Duke University, which focuses on the regulatory role of nitric oxide (NO) in the cardiovascular system. In particular, Dr. Stamler will outline the rationale behind the development of NO-based therapeutic modality in the management of patients with heart failure. The risk of sudden cardiac death in heart failure patients is six to nine times greater than that of the general population. Heart failure is responsible for 280,000 deaths annually in the US.
Dr. Stamler's presentation will be preceded by a short corporate overview by Cordex's chief executive officer, James S. Kuo, MD, MBA, and an update by the Company's chief scientific officer, Amir Pelleg, PhD, on the Company's lead drug candidate, ATPace, for the treatment and diagnosis of cardiac arrhythmias. Cordex expects to initiate a pivotal Phase 3 clinical trial with ATPace. The Phase 3 protocol is currently under consideration by the FDA under a Special Protocol Assessment provision.
Cordex's event will be held at the Yale Club in New York City. A buffet lunch will be provided beginning at 11:30 a.m. EST. Due to meeting room size limitations, in person attendance is by invitation only. To request an invitation, please call Redington Inc. at (212) 926-1733.
A webcast of the presentation can be accessed by any registered participants and will be made available at Page: 1 2 3 4 5 Related biology technology :1
. Axikin Pharmaceuticals Spins out of Actimis2
. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences3
. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine4
. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 20155
. Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry6
. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer7
. Cumberland Pharmaceuticals Appoints Lee Product Director8
. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program9
. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross10
. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference11
. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing